363 related articles for article (PubMed ID: 18629558)
1. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.
Carbonell-Estrany X; Bont L; Doering G; Gouyon JB; Lanari M
Eur J Clin Microbiol Infect Dis; 2008 Oct; 27(10):891-9. PubMed ID: 18629558
[TBL] [Abstract][Full Text] [Related]
2. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
3. Lower respiratory tract illness and RSV prophylaxis in very premature infants.
Lacaze-Masmonteil T; Truffert P; Pinquier D; Daoud P; Goldfarb G; Vicaut E; Fauroux B
Arch Dis Child; 2004 Jun; 89(6):562-7. PubMed ID: 15155404
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
[TBL] [Abstract][Full Text] [Related]
6. Are late preterm infants as susceptible to RSV infection as full term infants?
Resch B; Paes B
Early Hum Dev; 2011 Mar; 87 Suppl 1():S47-9. PubMed ID: 21276672
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
[TBL] [Abstract][Full Text] [Related]
8. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.
Papenburg J; Defoy I; Massé E; Caouette G; Lebel MH
J Pediatric Infect Dis Soc; 2021 Apr; 10(3):237-244. PubMed ID: 32530035
[TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
[TBL] [Abstract][Full Text] [Related]
10. Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study.
Papenburg J; Saleem M; Teselink J; Li A; Caouette G; Massé É; Lanctôt KL
Pediatr Infect Dis J; 2020 Aug; 39(8):694-699. PubMed ID: 32379195
[TBL] [Abstract][Full Text] [Related]
11. The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States.
Ektare V; Lang J; Choi Y; Finelli L
Vaccine; 2022 Oct; 40(42):6064-6073. PubMed ID: 36096968
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
14. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
15. [The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain].
Lázaro y de Mercado P; Figueras Aloy J; Doménech Martínez E; Echániz Urcelay I; Closa Monasterolo R; Wood Wood MA; Fitch Warner K
An Pediatr (Barc); 2006 Oct; 65(4):316-24. PubMed ID: 17020726
[TBL] [Abstract][Full Text] [Related]
16. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
[TBL] [Abstract][Full Text] [Related]
17. Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina.
Maksić H; Heljić S; Skokić F; Šumanović-Glamuzina D; Milošević V; Zlatanović A; Gerard N
Bosn J Basic Med Sci; 2018 Aug; 18(3):279-288. PubMed ID: 29750895
[TBL] [Abstract][Full Text] [Related]
18. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
[TBL] [Abstract][Full Text] [Related]
19. An outbreak of RSV infections in a neonatology clinic during the RSV-season.
Vakrilova L; Nikolova SH; Slavov S; Radulova P; Slancheva B
BMC Pediatr; 2021 Dec; 21(1):567. PubMed ID: 34895173
[TBL] [Abstract][Full Text] [Related]
20. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
